Pictet Asset Management Holding SA Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Pictet Asset Management Holding SA reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 22.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,793,931 shares of the biopharmaceutical company's stock after selling 788,652 shares during the quarter. Pictet Asset Management Holding SA owned approximately 1.79% of TG Therapeutics worth $84,097,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of TGTX. New Age Alpha Advisors LLC bought a new position in shares of TG Therapeutics during the 4th quarter worth approximately $213,000. Norges Bank purchased a new position in TG Therapeutics in the fourth quarter worth $12,085,000. Segall Bryant & Hamill LLC grew its stake in TG Therapeutics by 51.8% in the 4th quarter. Segall Bryant & Hamill LLC now owns 79,518 shares of the biopharmaceutical company's stock valued at $2,393,000 after purchasing an additional 27,128 shares during the period. Vanguard Group Inc. grew its stake in TG Therapeutics by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock valued at $469,454,000 after purchasing an additional 209,190 shares during the period. Finally, LPL Financial LLC increased its position in shares of TG Therapeutics by 61.9% during the 4th quarter. LPL Financial LLC now owns 185,062 shares of the biopharmaceutical company's stock valued at $5,570,000 after purchasing an additional 70,740 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX traded down $0.74 during midday trading on Thursday, hitting $39.08. The company's stock had a trading volume of 754,180 shares, compared to its average volume of 3,069,054. The firm has a market capitalization of $6.14 billion, a price-to-earnings ratio of -390.76 and a beta of 2.13. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a fifty day moving average price of $34.94 and a 200 day moving average price of $30.67. TG Therapeutics, Inc. has a one year low of $12.93 and a one year high of $43.32.

Remove Ads

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. On average, research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Buying and Selling

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company's stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, TG Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.